Article

A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression

National Institute of Mental Health (NIMH), 베서스다, Maryland, United States
Archives of General Psychiatry (Impact Factor: 14.48). 09/2006; 63(8):856-64. DOI: 10.1001/archpsyc.63.8.856
Source: PubMed

ABSTRACT

Existing therapies for major depression have a lag of onset of action of several weeks, resulting in considerable morbidity. Exploring pharmacological strategies that have rapid onset of antidepressant effects within a few days and that are sustained would have an enormous impact on patient care. Converging lines of evidence suggest the role of the glutamatergic system in the pathophysiology and treatment of mood disorders.
To determine whether a rapid antidepressant effect can be achieved with an antagonist at the N-methyl-D-aspartate receptor in subjects with major depression.
A randomized, placebo-controlled, double-blind crossover study from November 2004 to September 2005.
Mood Disorders Research Unit at the National Institute of Mental Health. Patients Eighteen subjects with DSM-IV major depression (treatment resistant).
After a 2-week drug-free period, subjects were given an intravenous infusion of either ketamine hydrochloride (0.5 mg/kg) or placebo on 2 test days, a week apart. Subjects were rated at baseline and at 40, 80, 110, and 230 minutes and 1, 2, 3, and 7 days postinfusion. Main Outcome Measure Changes in scores on the primary efficacy measure, the 21-item Hamilton Depression Rating Scale.
Subjects receiving ketamine showed significant improvement in depression compared with subjects receiving placebo within 110 minutes after injection, which remained significant throughout the following week. The effect size for the drug difference was very large (d = 1.46 [95% confidence interval, 0.91-2.01]) after 24 hours and moderate to large (d = 0.68 [95% confidence interval, 0.13-1.23]) after 1 week. Of the 17 subjects treated with ketamine, 71% met response and 29% met remission criteria the day following ketamine infusion. Thirty-five percent of subjects maintained response for at least 1 week.
Robust and rapid antidepressant effects resulted from a single intravenous dose of an N-methyl-D-aspartate antagonist; onset occurred within 2 hours postinfusion and continued to remain significant for 1 week.

Download full-text

Full-text

Available from: Jaskaran Singh
  • Source
    • "**P < 0. 01 and ***P < 0.001 compared with the saline-treated control. depressive disorders exhibited a significant anti-depressant effect [9]. Furthermore, it is also notable that antagonists at NMDA receptor display synergistic antidepressant-like property with standard antidepressants in the FST [10]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In the current study, the involvement of N-methyl-D-aspartate receptor (NMDAR) and nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) system in the antidepressant-like effects of baclofen was evaluated by using animal model in forced swimming test. Followed by an open field test for the evaluation of locomotor activity, the immobility time for mice in force swimming test was recorded. Only the last four min was analyzed. Administration of Baclofen (0.5 and 1mg/kg, i.p.) reduced the immobility interval in the FST. Prior administration of l-arginine (750mg/kg, i.p.,) a nitric oxide synthase substrate or sildenafil (5mg/kg, i.p.) a phosphodiesterase 5 into mice suppressed the antidepressant-like activity of baclofen (1mg/kg, i.p.).Co-treatment of 7-nitroindazole (50mg/kg, i.p.,) an inhibitor of neuronal nitric oxide synthase, L-NAME (10mg/kg, i.p.,) a non-specific inhibitor of nitric oxide synthase or MK-801 (0.05mg/kg, i.p.) an NMDA receptor antagonist with subeffective dose of baclofen (0.1mg/kg, i.p.), reduced the immobility time in the FST as compared to the drugs when used alone. Co-administrated of lower doses of MK-801 (0.01mg/kg) or L-NAME (1mg/kg) failed to effect immobility time however, simultaneous administration of these two agents in same dose with subeffective dose of baclofen (0.1mg/kg, i.p.), minimized the immobility time in the FST. Thus, our results support the role of NMDA receptors and l-arginine-NO-GMP pathway in the antidepressant-like action of baclofen.
    Full-text · Article · Dec 2015 · Neuroscience Letters
  • Source
    • "N-methyl-D-aspartate receptors are being increasingly studied as therapeutic targets in major depressive disorder (MDD). Ketamine, a nonselective NMDA receptor antagonist mainly used as a dissociative anesthetic, has been shown to induce rapid (within 24 h) antidepressant effects at subanesthetic doses (often administered intravenously at 0.5 mg kg À1 for 40 min) and the responses are sustained for several days after a single infusion (Berman et al. 2000; Zarate et al. 2006; DiazGranados et al. 2010; Valentine et al. 2011; Sanacora et al. 2012; Howland 2013). N-methyl-D-aspartate receptor antagonists specific for GluN2B (e.g., ifenprodil) are believed to act as allosteric modulators of the receptor, binding at the interface of the GluN1/GluN2B amino-terminal domain (Bhatt et al. 2013; Karakas and Furukawa 2014). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The preclinical pharmacodynamic and pharmacokinetic properties of 4-methylbenzyl (3S, 4R)-3-fluoro-4-[(Pyrimidin-2-ylamino) methyl] piperidine-1-carboxylate (CERC-301), an orally bioavailable selective N-methyl-D-aspartate (NMDA) receptor subunit 2B (GluN2B) antagonist, were characterized to develop a translational approach based on receptor occupancy (RO) to guide CERC-301 dose selection in clinical trials of major depressive disorder. CERC-301 demonstrated high-binding affinity (Ki, 8.1 nmol L−1) specific to GluN2B with an IC50 of 3.6 nmol L−1 and no off-target activity. CERC-301 efficacy was demonstrated in the forced swim test with an efficacy dose (ED50) of 0.3–0.7 mg kg−1 (RO, 30–50%); increase in locomotor activity was observed at ED50 of 2 mg kg−1, corresponding to an RO of 75%. The predicted 50% RO concentration (Occ50) in humans was 400 nmol L−1, similar to that predicted for rat, dog, and monkey (300, 200, and 400 nmol L−1, respectively). Safety pharmacology and neurotoxicity studies raised no specific safety concerns. A first-in-human study in healthy males demonstrated a dose-proportional pharmacokinetic profile, with Tmax of ~1 h and t1/2 of 12–17 h. Based on the preclinical and pharmacodynamic data, doses of ≥8 mg in humans are hypothesized to have an acceptable safety profile and result in clinically relevant peak plasma exposure.
    Preview · Article · Dec 2015
  • Source
    • "Patients in the 2 BD trials (Diazgranados et al., 2010a; Zarate et al., 2012) were drug free except for lithium or valproate. In the other 7 trials, patients were drug free in 2 (Berman et al., 2000; Zarate et al., 2006), allowed to take only a nonbenzodiazepine hypnotic in one (Murrough et al., 2013), and taking stable doses of other psychotropic medications in 4 trials (Sos et al., 2013; Lai et al., 2014; Lapidus et al., 2014) ( "

    Full-text · Article · Nov 2015 · The International Journal of Neuropsychopharmacology
Show more